Sana Biotechnology rises as cell transplant shows promise in type 1 diabetes treatment

Sana Biotechnology

13/03/2026 13:15

** Shares of biotech firm Sana Biotechnology SANA.O rise 5.2% to $3.25 premarket

** Co said an experimental cell transplant for type 1 diabetes showed insulin production for 14 months without immune‑suppressing drugs

** Type 1 diabetes is an autoimmune disease where the body destroys insulin‑making cells, forcing patients to rely on injections

** Co says transplanted insulin‑producing cells survived, avoided immune attack and released insulin in response to meals, based on C‑peptide data

** Study used a low dose to test safety and cell function; no safety issues were seen, co says

** Shares up about threefold in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))